Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis

被引:62
|
作者
Wei, Wenhui [1 ]
Anderson, Peter [2 ]
Gadkari, Abhijit [3 ]
Blackburn, Stuart [2 ]
Moon, Rachel [2 ]
Piercy, James [2 ]
Shinde, Shashank [1 ]
Gomez, Jorge [3 ]
Ghorayeb, Eric [1 ]
机构
[1] Sanofi, Bridgewater, MA USA
[2] Adelphi Real World, Bollington, Cheshire, England
[3] Regeneron Pharmaceut Inc, New York, NY USA
来源
JOURNAL OF DERMATOLOGY | 2018年 / 45卷 / 02期
关键词
atopic dermatitis; burden; disease control; patient-reported outcomes; quality of life; QUALITY-OF-LIFE; ECZEMA AREA; ACTIVITY IMPAIRMENT; WORK PRODUCTIVITY; JAPANESE PATIENTS; INDEX EASI; BURDEN; GUIDELINES; MANAGEMENT; IMPACT;
D O I
10.1111/1346-8138.14116
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Since control of atopic dermatitis (AD) remains challenging but has not been adequately characterized, the objective of this study was to characterize disease control among patients with a history of moderate to severe AD. Data were from the 2014 Adelphi US AD Disease Specific Programme, a cross-sectional survey of physicians (n=202) and their patients with history of moderate to severe AD (n=1064, 54% female, 75% white, mean age 40years). Inadequately controlled AD as rated by the physician was defined as currently flaring; deteriorating/changeable AD; or physician dissatisfaction with current control. The overall inadequate control rate was 58.7% (n=625), which increased with current AD severity and was observed in 53.4% and 83.4% of patients receiving immunosuppressants and systemic corticosteroids, respectively. Relative to controls, inadequately controlled patients had poorer disease-specific quality of life, higher level of work impairment, greater itch and sleep interference with daily living (all P<0.05). Multivariate analysis showed factors significantly associated with inadequate control (all P<0.05), including Hispanic race, symptoms on the head/neck or lower limbs, itch and sleep interference with daily living. A limitation of the study was reliance on accuracy of reporting, potential selection bias and cross-sectional study design. In summary, there was a high rate and substantial impact of physician-rated inadequately controlled disease among patients with a history of moderate to severe AD, suggesting the need for more effective therapies.
引用
收藏
页码:150 / 157
页数:8
相关论文
共 50 条
  • [1] Extent and consequences of inadequate disease control among adults with a history of moderate-to-severe atopic dermatitis
    Wei, W.
    Anderson, P.
    Gadkari, A.
    Blackburn, S.
    Moon, R.
    Piercy, J.
    Shinde, S.
    Gomez, J.
    Ghorayeb, E.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (05) : S23 - S23
  • [2] Extent and Impact of Inadequate Disease Control in US Adults with a History of Moderate to Severe Atopic Dermatitis Following Introduction of New Treatments
    Andreas Westh Vilsbøll
    Peter Anderson
    James Piercy
    Gary Milligan
    Nana Kragh
    Dermatology and Therapy, 2021, 11 : 475 - 486
  • [3] Extent and Impact of Inadequate Disease Control in US Adults with a History of Moderate to Severe Atopic Dermatitis Following Introduction of New Treatments
    Vilsboll, Andreas Westh
    Anderson, Peter
    Piercy, James
    Milligan, Gary
    Kragh, Nana
    DERMATOLOGY AND THERAPY, 2021, 11 (02) : 475 - 486
  • [4] Atopic Dermatitis With a Focus on Moderate to Severe Disease
    Aldredge, Lakshi M.
    JNP-JOURNAL FOR NURSE PRACTITIONERS, 2020, 16 (10): : 726 - 731
  • [5] A Treatment Algorithm for Moderate to Severe Atopic Dermatitis in Adults
    Lynde, Charles W.
    Bourcier, Marc
    Gooderham, Melinda
    Guenther, Lyn
    Hong, Chih-ho
    Papp, Kim A.
    Poulin, Yves
    Sussman, Gordon
    Vender, Ronald
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2018, 22 (01) : 78 - 83
  • [6] Validation of the pruritus and symptoms assessment for atopic dermatitis in adults with moderate-to-severe atopic dermatitis
    Lebwohl, M. G.
    Simpson, E. L.
    Bushmakin, A. G.
    Cappelleri, J. C.
    Gooderham, M. J.
    Wollenberg, A.
    Hall, R.
    Gater, A.
    Wells, J. R.
    Papacharalambous, J.
    Hsu, M. A.
    Tallman, A. M.
    Peeva, E.
    Zhang, W.
    Chen, L.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (01) : E44 - E44
  • [7] Alefacept for moderate to severe atopic dermatitis: A pilot study in adults
    Moul, Danielle K.
    Routhouska, Shannon B.
    Robinson, Maria R.
    Korman, Neil J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (06) : 984 - 989
  • [8] Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
    Beck, Lisa A.
    Thaci, Diamant
    Hamilton, Jennifer D.
    Graham, Neil M.
    Bieber, Thomas
    Rocklin, Ross
    Ming, Jeffrey E.
    Ren, Haobo
    Kao, Richard
    Simpson, Eric
    Ardeleanu, Marius
    Weinstein, Steven P.
    Pirozzi, Gianluca
    Guttman-Yassky, Emma
    Suarez-Farinas, Mayte
    Hager, Melissa D.
    Stahl, Neil
    Yancopoulos, George D.
    Radin, Allen R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (02): : 130 - 139
  • [9] Impact of dupilumab treatment on seasonal disease severity in adults with moderate-to-severe atopic dermatitis
    Beck, Lisa A.
    Simpson, Eric L.
    Ramien, Michele
    Tang, Mark
    Joyce, Joel C.
    Praestgaard, Amy
    Rossi, Ana B.
    Clearfield, Drew
    Zhang, Annie
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [10] Advances in Systemic Treatment for Adults With Moderate-to-Severe Atopic Dermatitis
    Cho, Yung-Tsu
    Chu, Chia-Yu
    DERMATOLOGICA SINICA, 2019, 37 (01) : 3 - 11